In addition to the 13 – institution New Approaches to Neuroblastoma Therapy group is now active uses .
Grid computing work was one of the ‘ten technologies that will change the world ‘was MIT Technology Review MIT Technology Review, and a ‘Best received 100 ‘award and a ‘Most Promising New Technology ‘award from R & D Magazine.
Become The biomarker study are approximately 12 experienced patients with stable schizophrenic who sign receive atypical antipsychotic therapeutic threads MEM randomly assigned 3 454 and placebo receive in one 5-way crossover design Every subject is to participate in 5 treatment time While everyone. Period, the volunteers received a single dose from 1 mg, 15 mg or glucose 50 mg MEM 3 454 and placebo, using a 4-day washout period between each treatment stage. The primary aim which study is to P50 sensory gating and mismatch negativity than potential effectiveness biomarker to nicotinic alpha – 7 agonists, as MEM studies 3 454 at, in schizophrenia. P 50 sensorial gating and mismatch negativity have two neurophysiological measurements who have shown nicotinic closely associated with nicotinic alpha – 7 application and schizophrenia.
The are subject to news release contains forward -looking statements under Private Securities Litigation Reform Act of 1995 to risks and insecurities. All the statements other than statements of historical fact, through management’s expectations, beliefs, plans or Memory Pharmaceuticals ‘ prospects for of future financial position, clinical investigators, and projected costs forward forward-looking. Readers will note that actual results to may differ materially from prognoses or estimates based a number of factors , including the risks and uncertainties relating to with: to obtain additional financing of supported Memory Pharmaceuticals ‘ R and E and clinical activities and operations, the output of clinical trials, Memory Pharmaceuticals ‘ drug candidates and whether it illustrate these candidate security and effectiveness, and governmental approvals trials trials and in Memory Pharmaceuticals market ‘drug candidates; received Memory Pharmaceuticals’ ability and nurture cooperation with third parties of his development of drugs programs, Memory ‘ ‘ depending upon its collaborative and their licensing relationships; reach milestone into Memory Pharmaceuticals ‘ partnerships; Memory Pharmaceuticals ‘ a function of preclinical and clinical investigators, of preclinical and clinical research, manufacturers and consultants, forward looking statements developed from or licensed to Memory Pharmaceuticals. This and other risks described in detail in Memory Pharmaceuticals ‘ filings with the Securities and Exchange Commission. In Memory Pharmaceuticals is not really achieving the objectives and plans described in at its forward-looking statements, and investment should not place undue reliance on these statements. In Memory Pharmaceuticals disclaims any intention or undertake to update any forward-looking statement as a result of developments in, that to upgrade after the date of this press release.